What are the recommended infusion rates in milliliters per hour for common inotropic agents (dobutamine, dopamine, norepinephrine, epinephrine, levosimendan, milrinone, enoximone) for a typical 70‑kg adult, including starting doses and titration ranges?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Inotropic Infusion Rates for a 70-kg Adult

For a typical 70-kg adult, start dobutamine at 2.5 μg/kg/min (10.5 mL/hr using 200 μg/mL concentration) and titrate up to 20 μg/kg/min maximum; norepinephrine and epinephrine both start at 0.1–0.5 μg/kg/min (7–35 μg/min absolute dose); dopamine starts at 5–10 μg/kg/min; and milrinone requires a 50 μg/kg loading dose over 10 minutes followed by 0.375–0.75 μg/kg/min infusion.

Standard Concentrations and Infusion Rates

Dobutamine 1, 2, 3

  • Standard concentration: 1,000 μg/mL or 2,000 μg/mL
  • Starting dose: 2.5 μg/kg/min (for 70-kg adult = 175 μg/min)
    • Using 1,000 μg/mL: 10.5 mL/hr
    • Using 2,000 μg/mL: 5.25 mL/hr
  • Typical range: 5–10 μg/kg/min
    • 5 μg/kg/min (350 μg/min): 21 mL/hr (1,000 μg/mL) or 10.5 mL/hr (2,000 μg/mL)
    • 10 μg/kg/min (700 μg/min): 42 mL/hr (1,000 μg/mL) or 21 mL/hr (2,000 μg/mL)
  • Maximum: 20 μg/kg/min (1,400 μg/min): 84 mL/hr (1,000 μg/mL) or 42 mL/hr (2,000 μg/mL)
  • Titration: Double dose every 15 minutes according to response 2

The ESC guidelines emphasize that doses >20 μg/kg/min are rarely needed, and titration is typically limited by tachycardia, arrhythmias, or ischemia 2. Dobutamine has mild vasodilator activity due to beta-2 receptor stimulation, which can be advantageous in reducing afterload 1.

Dopamine 1

  • Standard concentration: Variable (typically 1,600–3,200 μg/mL)
  • Starting dose: 5–10 μg/kg/min (for 70-kg adult = 350–700 μg/min)
  • Dose-dependent effects:
    • 1–5 μg/kg/min: Dopaminergic and beta-adrenergic effects

    • 5 μg/kg/min: Alpha-adrenergic effects predominate

    • 20 μg/kg/min: Excessive vasoconstriction, avoid 4

Critical caveat: Low-dose dopamine for "renal protection" is not supported by evidence and should not be used for this indication 1.

Norepinephrine 1

  • Standard concentration: 16–32 μg/mL
  • Starting dose: 0.1–0.5 μg/kg/min (for 70-kg adult = 7–35 μg/min)
    • Using 16 μg/mL: 26–131 mL/hr
    • Using 32 μg/mL: 13–66 mL/hr
  • Typical range: 0.1–0.5 μg/kg/min, titrate to effect

Norepinephrine is preferred over dopamine due to lower arrhythmic risk and superior safety profile 5, 6. It should be administered via central line whenever possible to prevent tissue necrosis from extravasation 1.

Epinephrine 1, 7

  • Standard concentration: 16–32 μg/mL
  • Starting dose: 0.1–0.5 μg/kg/min (for 70-kg adult = 7–35 μg/min)
    • Using 16 μg/mL: 26–131 mL/hr
    • Using 32 μg/mL: 13–66 mL/hr
  • Dose-dependent effects:
    • <0.3 μg/kg/min: Beta-adrenergic effects (inotropy, decreased SVR)

    • 0.3 μg/kg/min: Alpha-adrenergic vasoconstriction 4

Important warning: Recent evidence suggests epinephrine may be associated with adverse metabolic effects and higher rates of refractory shock compared to norepinephrine 5, 6. Consider as second-line agent.

Milrinone 1, 8, 9

  • Standard concentration: 200 μg/mL
  • Loading dose: 50 μg/kg over 10 minutes (for 70-kg adult = 3,500 μg = 17.5 mL)
  • Maintenance infusion:
    • Minimum: 0.375 μg/kg/min (26.25 μg/min): 7.9 mL/hr
    • Standard: 0.5 μg/kg/min (35 μg/min): 10.5 mL/hr
    • Maximum: 0.75 μg/kg/min (52.5 μg/min): 15.8 mL/hr

Milrinone has a long half-life (2.5 hours) with delayed steady-state effects 9. Loading dose may be omitted in non-urgent situations to avoid hypotension. Dose adjustment required in renal impairment 9.

Levosimendan (Limited availability in some regions)

  • Standard concentration: Variable
  • Loading dose: 6–12 μg/kg over 10 minutes (often omitted to avoid hypotension)
  • Maintenance infusion: 0.05–0.2 μg/kg/min
    • For 70-kg adult: 3.5–14 μg/min
  • Duration: Typically 24 hours

Levosimendan may offer selective splanchnic perfusion benefits 10, 11 and has been used successfully in refractory shock when mechanical support is unavailable 11.

Enoximone (Less commonly used)

  • Maintenance infusion: 2.5–10 μg/kg/min 12
  • For 70-kg adult: 175–700 μg/min
  • Note: Evidence of nonlinear pharmacokinetics with potential for accumulation during prolonged infusion 12

Practical Preparation Guidelines

Mixing Standard Concentrations 3, 9

Dobutamine (to achieve 1,000 μg/mL):

  • 250 mg in 250 mL = 1,000 μg/mL
  • 500 mg in 500 mL = 1,000 μg/mL

Milrinone (to achieve 200 μg/mL):

  • 20 mg in 100 mL total volume (20 mL drug + 80 mL diluent)
  • 10 mg in 50 mL total volume (10 mL drug + 40 mL diluent)

Compatible diluents: 0.9% NaCl, 0.45% NaCl, 5% Dextrose, Lactated Ringer's 3, 9

Critical Safety Considerations

Extravasation Management 1, 7

If extravasation of catecholamines occurs:

  • Immediately infiltrate: Phentolamine 5–10 mg diluted in 10–15 mL saline into extravasation site
  • Prevention: Use central venous access whenever possible for norepinephrine, epinephrine, dopamine, and dobutamine

Drug Incompatibilities 1

  • Never mix adrenergic drugs with sodium bicarbonate or alkaline solutions (causes inactivation)
  • Dobutamine should not be mixed with agents containing both sodium bisulfite and ethanol 3

Monitoring Requirements 1

  • Continuous arterial blood pressure monitoring recommended
  • Target mean arterial pressure ≥65 mmHg 1
  • Central venous oxygen saturation (ScvO₂) ≥70% 1
  • Titrate to clinical endpoints: urine output, mental status, skin perfusion, lactate clearance

Common Adverse Effects 1, 4, 8

All catecholamines can cause:

  • Tachyarrhythmias (dose-limiting)
  • Myocardial ischemia (increased oxygen demand)
  • Hyperglycemia
  • Hypokalemia
  • Increased lactate production

Clinical Decision Algorithm

For cardiogenic shock with hypotension (SBP <85 mmHg) 2:

  1. Start norepinephrine 0.1 μg/kg/min (preferred vasopressor) 5, 6
  2. Add dobutamine 2.5 μg/kg/min if cardiac output remains low despite adequate blood pressure 2, 8
  3. Consider milrinone if high systemic vascular resistance or if tachycardia limits dobutamine dose 8

For cardiogenic shock with adequate blood pressure (SBP 85–110 mmHg) 2:

  1. Start dobutamine 2.5 μg/kg/min, titrate every 15 minutes 2
  2. Monitor closely for hypotension; add vasopressor if SBP drops <85 mmHg

For refractory shock 6, 11:

  1. Maximize single-agent therapy before adding second agent
  2. Consider mechanical circulatory support if available
  3. Levosimendan may be considered as bridge therapy when MCS unavailable 11

Key principle: The 2022 AHA/ACC/HFSA guidelines emphasize that no single inotrope has demonstrated mortality benefit 8. Choice should be based on hemodynamic profile, side effect tolerance, and institutional familiarity rather than survival expectations 5, 6. Dobutamine and milrinone are equivalent for mortality outcomes (high certainty evidence) 8.

References

6
Research

Pharmacological treatment of cardiogenic shock.

Current opinion in critical care, 2026

Related Questions

For a patient with cardiogenic shock and chest pain, should dobutamine be combined with phenylephrine (Neosynephrine) or should norepinephrine be used as the primary pressor?
In which types of shock are adrenaline (epinephrine) and milrinone used?
In a patient with cardiogenic shock and bradycardia, should levosimendan (inodilator) be preferred over dobutamine (beta‑agonist) as the inotropic therapy?
What is the appropriate dobutamine dosage for an adult patient with cardiogenic shock?
What is the recommended management of cardiogenic shock, including stabilization, pharmacologic therapy, and mechanical circulatory support?
What is the appropriate management for a 44-year-old man with obesity (BMI 40), asthma, hemoglobin A1c 5.9%, LDL cholesterol 209 mg/dL, total cholesterol 279 mg/dL, and HDL cholesterol 41 mg/dL?
What could cause a brief left intercostal discomfort that occurs shortly after meals in a patient with hypercholesterolemia and gastro‑oesophageal reflux disease?
What is the most appropriate benzodiazepine for a patient on methadone and multiple diuretics who requires acute rescue treatment for breakthrough tonic‑clonic seizures?
Is diclofenac appropriate for acute treatment of migraine in adults, and what dosing and contraindications should be considered?
How should warfarin be initiated, dosed, monitored, and adjusted in a patient with a mechanical mitral valve prosthesis?
What is the appropriate management for a 46-year-old man with a two‑month history of left‑eye visual‑field defect (nasal hemianopia and inferior altitudinal scotoma on perimetry), normal visual acuity, probable left relative afferent pupillary defect (RAPD) and optic‑disc pallor?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.